|
|
???tair.name??? >
???browser.page.title.author???
|
"kim sang we"???jsp.browse.items-by-author.description???
Showing items 1-9 of 9 (1 Page(s) Totally)
1
View [10|25|50] records per page
| 臺大學術典藏 |
2020-07-07T08:21:02Z |
Osimertinib in Patients With Epidermal Growth Factor Receptor Mutation-Positive Non-Small-Cell Lung Cancer and Leptomeningeal Metastases: The BLOOM Study
|
Kim, Tae Min; Goldman, Jonathan W.; Natale, Ronald B.; Brown, Andrew P.; Collins, Barbara; Chmielecki, Juliann; Vishwanathan, Karthick; Mendoza-Naranjo, Ariadna; Ahn, Myung-Ju; Stathes Paganis; Lee, Dae H.; Ahn, Jin-Seok; Yang, James C.H.; Kim, Sang-We; Kim, Dong-Wan; Lee, Jong-Seok; Cho, Byoung Chul; Yang, James C.H.;Kim, Sang-We;Kim, Dong-Wan;Lee, Jong-Seok;Cho, Byoung Chul;Ahn, Jin-Seok;Lee, Dae H.;Kim, Tae Min;Goldman, Jonathan W.;Natale, Ronald B.;Brown, Andrew P.;Collins, Barbara;Chmielecki, Juliann;Vishwanathan, Karthick;Mendoza-Naranjo, Ariadna;Ahn, Myung-Ju |
| 臺大學術典藏 |
2019-03-04T08:08:05Z |
Ramucirumab Safety in East Asian Patients: A Meta-Analysis of Six Global, Randomized, Double-Blind, Placebo-Controlled, Phase III Clinical Trials
|
Cheng, Rebecca;Chung, Hyun Cheol;Orlando, Mauro;Mi, Gu;Binder, Polina;Zhang, Yawei;Sohn, JooHyuk;Yamazaki, Kentaro;Kim, Sang-We;Chao, Yee;Lee, Keun-Wook;Kudo, Masatoshi;Kim, Tae-Won;Muro, Kei;Yen, Chia-Jui;JIN-YUAN SHIH; Yen, Chia-Jui; Muro, Kei; Kim, Tae-Won; Kudo, Masatoshi; JIN-YUAN SHIH; Lee, Keun-Wook; Chao, Yee; Kim, Sang-We; Yamazaki, Kentaro; Sohn, JooHyuk; Cheng, Rebecca; Zhang, Yawei; Binder, Polina; Mi, Gu; Orlando, Mauro; Chung, Hyun Cheol |
| 國立成功大學 |
2016-10 |
Phase II evaluation of LY2603618, a first-generation CHK1 inhibitor, in combination with pemetrexed in patients with advanced or metastatic non-small cell lung cancer
|
Scagliotti, Giorgio;Kang, Jin Hyoung;Smith, David;Rosenberg, Richard;Park, Keunchil;Kim, Sang-We;Su, Wu-Chou;Boyd, Thomas E.;Richards, Donald A.;Novello, Silvia;Hynes, Scott M.;Myrand, Scott P.;Lin, Ji;Smyth, Emily Nash;Wijayawardana, Sameera;Lin, Aimee Bence;Pinder-Schenck, Mary |
| 國立臺灣大學 |
2015 |
A randomized Phase 3 study comparing first-line pemetrexed plus cisplatin followed by gefitinib maintenance (PC/G) with gefitinib monotherapy (G) in East Asian patients (pts) with locally advanced or metastatic nonsquamous non-small cell lung cancer (nSqNSCLC): Final survival results.
|
Yang, James Chih-Hsin; Srimuninnimit, Vichien; Ahn, Myung-Ju; Lin, Chia-Chi; Kim, Sang-We; Tsai, Chun-Ming; Mok, Tony; Orlando, Mauro; Puri, Tarun; Wang, Xin; Park, Keunchil; 林家齊; 楊志新 |
| 國立臺灣大學 |
2015 |
Preliminary results of TATTON, a multi-arm phase Ib trial of AZD9291 combined with MEDI4736, AZD6094 or selumetinib in EGFR-mutant lung cancer.
|
Oxnard, Geoffrey R.; Ramalingam, Suresh S.; Ahn, Myung-Ju; Kim, Sang-We; Yu, Helena Alexandra; Saka, Hideo; Horn, Leora; Goto, Koichi; Ohe, Yuichiro; Cantarini, Mireille; Frewer, Paul; Lahn, Michael; Yang, James Chih-Hsin; 楊志新 |
| 國立臺灣大學 |
2015 |
Gefitinib plus chemotherapy versus placebo plus chemotherapy in EGFR-mutation- positive non-small-cell lung cancer after progression on first-line gefitinib (IMPRESS): a phase 3 randomised trial
|
Soria, Jean-Charles; Wu, Yi-Long; Nakagawa, Kazuhiko; Kim, Sang-We; Yang, Jin-Ji; Ahn, Myung-Ju; Wang, Jie; Yang, James Chih-Hsin; Lu, You; Atagi, Shinji; Ponce, Santiago; Lee, Dae Ho; Liu, Yunpeng; Yoh, Kiyotaka; Zhou, Jian-Ying; Shi, Xiaojin; Webster, Alan; Jiang, Haiyi; Mok, Tony S. K.; 楊志新 |
| 國立臺灣大學 |
2015 |
AZD9291 in EGFR Inhibitor-Resistant Non-Small-Cell Lung Cancer
|
Jaenne, Pasi A.; Yang, James Chih-Hsin; Kim, Dong-Wan; Planchard, David; Ohe, Yuichiro; Ramalingam, Suresh S.; Ahn, Myung-Ju; Kim, Sang-We; Su, Wu-Chou; Horn, Leora; Haggstrom, Daniel; Felip, Enriqueta; Kim, Joo-Hang; Frewer, Paul; Cantarini, Mireille; Brown, Kathryn H.; Dickinson, Paul A.; Ghiorghiu, Serban; Ranson, Malcolm; 楊志新 |
| 國立成功大學 |
2012-05 |
Afatinib versus placebo for patients with advanced, metastatic non-small-cell lung cancer after failure of erlotinib, gefitinib, or both, and one or two lines of chemotherapy (LUX-Lung 1): a phase 2b/3 randomised trial
|
Miller, Vincent A.; Hirsh, Vera; Cadranel, Jacques; Chen, Yuh-Min; Park, Keunchil; Kim, Sang-We; Zhou, Caicun; Su, Wu-Chou; Wang, Mengzhao; Sun, Yan; Heo, Dae Seog; Crino, Lucio; Tan, Eng-Huat; Chao, Tsu-Yi; Shahidi, Mehdi; Cong, Xiuyu Julie; Lorence, Robert M.; Yang, James Chih-Hsin |
| 國立臺灣大學 |
2012 |
Afatinib versus placebo for patients with advanced, metastatic non-small-cell lung cancer after failure of erlotinib, gefitinib, or both, and one or two lines of chemotherapy (LUX-Lung 1): a phase 2b/3 randomised trial
|
Miller, Vincent A.; Hirsh, Vera; Cadranel, Jacques; Chen, Yuh-Min; Park, Keunchil; Kim, Sang-We; Zhou, Caicun; Su, Wu-Chou; Wang, Mengzhao; Sun, Yan; Heo, Dae Seog; Crino, Lucio; Tan, Eng-Huat; Chao, Tsu-Yi; Shahidi, Mehdi; Cong, Xiuyu Julie; Lorence, Robert M.; Yang, James Chih-Hsin; 楊志新 |
Showing items 1-9 of 9 (1 Page(s) Totally)
1
View [10|25|50] records per page
|
